Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A
NCT ID: NCT04874142
Last Updated: 2021-05-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2019-11-20
2020-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506
NCT04874129
Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.
NCT04858308
Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers
NCT06758661
A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
NCT07229937
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects
NCT02676596
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A Group
Two cohort, single sequence
YYC506-T
single administration
YYC506-T + YYC506-A
concomotant administration
B Group
Two cohort, single sequence
YYC506-A
single administration
YYC506-A + YYC506-T
concomotant administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YYC506-T
single administration
YYC506-A
single administration
YYC506-T + YYC506-A
concomotant administration
YYC506-A + YYC506-T
concomotant administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over 50.0kg, 18.0kg/m2 ≤ BMI ≤30.0kg/m2
* Men who dont have congenital disease and other cronic disease need to be cared etc.
Exclusion Criteria
* Men who have drunken or eatten something including carffeine within 24 hours before etc.
19 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yooyoung Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Min Kyu Park, PhD
Role: STUDY_CHAIR
ChungBuk National Unviersity Hospital.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ChungBuk National University Hospital
Cheongju-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YYPCT_YYC506_P1_DDI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.